[ad_1]
“Within a month from December 27th. A total of 68,491 people were vaccinated in Lithuania and the number of vaccinations was 84,586. There were more vaccinations, as some people have already received the second dose of the vaccine. During this period, out of the aforementioned number of people vaccinated and the number of vaccinations, the Lithuanian Medicines Control Agency received 311 initial reports of undesirable side effects, ”Gytis Andrulionis, head of IWT, reported at the press conference.
According to him, the notifications received represent 0.37 percent. of the number of doses vaccinated. G. Andulionis also emphasizes that in the general context of other countries, Lithuania does not stand out according to the reports received about the side effects of COVID-19 vaccines.
“There are countries where there is a higher percentage of reports of adverse reactions. For example, it is 0.48% in Norway, 0.33% in Ireland and 0.8% in Estonia. But there are countries with a much lower record, that is, Germany with 0.06 percent. But when we try to assess the average, we are not exceptional, “he said.
The IWT director also claims that Pfizer-BioNTech has received 297 reports of adverse reactions to Comirnaty and 13 reports of serious adverse reactions to Moderna.
“This is due to the fact that the Moderna vaccination was not launched until January 18. Vaccination starts only from that date and there are 15 and 90 days to report adverse reactions, respectively. All messages may not have reached us yet. “
“We receive the vast majority of reports of adverse reactions from patients.
Mr. Andulionis also reported that 13 reports of serious adverse reactions to COVID-19 had been received.
“Mild reactions to the vaccine accounted for the absolute majority, 284 for Comirnaty and 13 for Moderna. We also have 13 severe reactions,” he said.
IWT is responsible for recording adverse drug reactions. The mandate of the Authority includes the recording, analysis and entry of adverse reactions in the European pharmacovigilance database.
No part of this publication may be reproduced without the written permission of ELTA.
[ad_2]
